Eli Lilly and Company (LLY) — closed signal from May 2, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 31, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$925.00 – $965.00Entry zone — fair-value band
$963.33Published — price the day we called it
$1,107.83Target — the price the thesis aimed for
$1,249.45Peak — highest point inside the window, not a realized return
$1,148.84Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 26 days.
Peak price
$1,249.45
peak on July 7, 2026 — not a realized returnPeak gain
+29.7%
peak, from the publication priceWindow close
$1,148.84
end-of-window price, context onlyDays to target
26
Window
May 2, 2026 – July 31, 2026
The thesis — published May 2, 2026
Predicted growth
+15%
over the measurement windowTarget price
$1,107.83
the price the thesis aimed forEntry zone
$925.00 – $965.00
the fair-value band we waited forPrice at publication
$963.33
published May 2, 2026Confidence
79%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Eli Lilly combines strong medical products with a clear growth story driven by GLP-1 drugs and an early-stage oral weight-loss medicine. Recent results and pricing comments look solid, but the share price has already moved up a lot. Short-term gains are likelier if the stock cools and resumes its trend; leverage and crowded ownership limit upside.
Primary drivers
- Growing demand for GLP-1 drugs that boost sales over time
- Early momentum for an oral weight-loss prescription supports growth
- Consistent quarterly wins show the company can deliver results
- Healthcare mix helps smooth cycles while still allowing growth
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.